Design, synthesis and biological evaluation of tricyclic pyrazolo[1,5-c][1,3]benzoxazin-5(5H)-one scaffolds as selective BuChE inhibitors

References

• Mucke L. Neuroscience: Alzheimer’s disease. Nature 2009;461:895–7.
   PubMed Web of Science ®Google Scholar
• Pivtoraiko VN, Abrahamson EE, Leurgans SE, et al. Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer’s disease. Neurobiol Aging 2015;36:12–19.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2016;12:459–509.
   PubMedGoogle Scholar
• Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer Disease. Cold Spring Harb Perspect Med 2012;2:a006262.
   PubMed Web of Science ®Google Scholar
• Avila J. Tau phosphorylation and aggregation in Alzheimer’s disease pathology. FEBS Lett 2006;580:2922–7.
   PubMed Web of Science ®Google Scholar
• Müller ML, Bohnen NI. Cholinergic dysfunction in Parkinson’s disease. Curr Neurol Neurosci Rep 2013;13:377.
   PubMed Web of Science ®Google Scholar
• Rosini M, Simoni E, Milelli A, et al. Oxidative stress in Alzheimer's disease: are we connecting the dots? J Med Chem 2014;57:2821–31.
   PubMed Web of Science ®Google Scholar
• Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet 2016;388:505–17.
   PubMed Web of Science ®Google Scholar
• Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053–65.
   PubMed Web of Science ®Google Scholar
• Mushtaq G, Greig NH, Khan JA, Kamal MA. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014;13:1432–9.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Catto M, Tasso B, et al. Multitarget therapeutic leads for Alzheimer's disease: quinolizidinyl derivatives of bi- and tricyclic systems as dual inhibitors of cholinesterases and β-Amyloid (Aβ) aggregation. ChemMedChem 2015;10:1040–53.
   PubMed Web of Science ®Google Scholar
• Zhou D, Zhou W, Song JK, et al. DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against Aβ-induced neuronal damage via the Akt/JNK signaling pathway. Acta Pharmacol Sin 2016;37:1401–12.
   PubMed Web of Science ®Google Scholar
• Asadipour A, Alipour M, Jafari M, et al. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem 2013;70:623–30.
   PubMed Web of Science ®Google Scholar
• Liu HR, Fan HQ, Gao XH, et al. Design, synthesis and preliminary structure–activity relationship investigation of nitrogen-containing chalcone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors: a further study based on Flavokawain B Mannich base derivatives. J Enzyme Inhib Med Chem 2016;31:580–9.
   PubMed Web of Science ®Google Scholar
• Farina R, Pisani L, Catto M, et al. Structure-based design and optimization of multitarget-directed 2H-chromen-2-one derivatives as potent inhibitors of monoamine oxidase B and cholinesterases. J Med Chem 2015;58:5561–78.
   PubMed Web of Science ®Google Scholar
• Bajda M, Więckowska A, Hebda M, et al. Structure-based search for new inhibitors of cholinesterases. Int J Mol Sci 2013;14:5608–32.
   PubMed Web of Science ®Google Scholar
• Liu H, Liu L, Gao X, et al. Novel ferulic amide derivatives with tertiary amine side chain as acetylcholinesterase and butyrylcholinesterase inhibitors: the influence of carbon spacer length, alkylamine and aromatic group. Eur J Med Chem 2017;126:810–22.
   PubMed Web of Science ®Google Scholar
• Appleyard ME, Smith AD, Berman P, et al. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Brain 1987;110:1309–22.
   PubMed Web of Science ®Google Scholar
• Norel X, Angrisani M, Labat C, et al. Degradation of acetylcholine in human airways: role of butyrylcholinesterase. Br J Pharmacol 1993;108:914–19.
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Tye S. Favorable impact on stress-related behaviors by modulating plasma butyrylcholinesterase. Cell Mol Neurobiol 2018;38:7–12.
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005;102:17213–18.
   PubMed Web of Science ®Google Scholar
• Nicolet Y, Lockridge O, Masson P, et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003;278:41141–7.
   PubMed Web of Science ®Google Scholar
• Brus B, Kosak U, Turk S, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem 2014;57:8167–79.
   PubMed Web of Science ®Google Scholar
• Csuk R, Albert S, Kluge R, et al. Resveratrol derived butyrylcholinesterase inhibitors. Arch Pharm (Weinheim) 2013;346:499–503.
   PubMed Web of Science ®Google Scholar
• Košak U, Brus B, Knez D, et al. Development of an in-vivo active reversible butyrylcholinesterase inhibitor. Sci Rep 2016;6:39495.
   PubMed Web of Science ®Google Scholar
• Gao XH, Zhou C, Liu HR, et al. Tertiary amine derivatives of chlorochalcone as acetylcholinesterase (AChE) and buthylcholinesterase (BuChE) inhibitors: the influence of chlorine, alkyl amine side chain and α,β-unsaturated ketone group. J Enzyme Inhib Med Chem 2017;32:146–52.
   PubMed Web of Science ®Google Scholar
• Košak U, Brus B, Knez D, et al. The magic of crystal structure-based inhibitor optimization: development of a butyrylcholinesterase inhibitor with picomolar affinity and in vivo activity. J Med Chem 2018;61:119–39.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu J, Mo J, et al. Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer's disease. J Enzyme Inhib Med Chem 2018;33:290–302.
   PubMed Web of Science ®Google Scholar
• Tasso B, Catto M, Nicolotti O, et al. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease. Eur J Med Chem 2011;46:2170–84.
   PubMed Web of Science ®Google Scholar
• Li Q, Yang H, Chen Y, et al. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. Eur J Med Chem 2017;132:294–309.
   PubMed Web of Science ®Google Scholar
• Secci D, Carradori S, Bolasco A, et al. Discovery and optimization of pyrazoline derivatives as promising monoamine oxidase inhibitors. Curr Top Med Chem 2012;12:2240–57.
   PubMed Web of Science ®Google Scholar
• Alex JM, Kumar R. 4,5-Dihydro-1H-pyrazole: an indispensable scaffold. J Enzyme Inhib Med Chem 2014;29:427–42.
   PubMed Web of Science ®Google Scholar
• Khan MF, Alam MM, Verma G, et al. The therapeutic voyage of pyrazole and its analogs: a review. Eur J Med Chem 2016;120:170–201.
   PubMed Web of Science ®Google Scholar
• Wu XQ, Huang C, Jia YM, et al. Novel coumarin-dihydropyrazole thio-ethanone derivatives: design, synthesis and anticancer activity. Eur J Med Chem 2014;74:717–25.
   PubMed Web of Science ®Google Scholar
• Qiang DZ, Shi JB, Song BA, et al. Novel 2H-chromen derivatives: design, synthesis and anticancer activity. RSC Adv 2014;4:5607–17.
   Web of Science ®Google Scholar
• Chen YY, Wu XQ, Tang WJ, et al. Novel dihydropyrazole-chromen: design and modulates hTERT inhibition proliferation of MGC-803. Eur J Med Chem 2016;110:65–75.
   PubMed Web of Science ®Google Scholar
• Tong X, Chen R, Zhang TT, et al. Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors. Bioorg Med Chem 2015;23:515–25.
   PubMed Web of Science ®Google Scholar
• Chen R, Xiao J, Ni Y, et al. Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: design, synthesis, model and use as hMAO-B inhibitors. Bioorg Med Chem 2016;24:1741.
   PubMed Web of Science ®Google Scholar
• Chen SC, Qiu GL, Li B, et al. Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: synthesis and biological evaluation as selective BuChE inhibitors. Eur J Med Chem 2018;147:194–204.
   PubMed Web of Science ®Google Scholar
• Nawwar GAM. Tetrachloro-o-benzoquinone in organic synthesis: a novel synthetic route to pyrazolo[1,5-c][1,3]benzoxazines and 5,7-disubstituted 4-hydroxycoumarins. J Chem Res Synop 2010;23:5.
   Google Scholar
• Svetlik J, Pronayova N, Kubista J. Synthesis of some pyrazolo[1,5-c][1,3]benzoxazines and a new 5H-pyrazolo[1,5-c][1,3,2]benzoxazaphosphorine ring system. J Heterocyclic Chem 2005;42:1143–7.
   Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002;10:279–88.
   PubMed Web of Science ®Google Scholar
• Zha X, Lamba D, Zhang L, et al. Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer's disease: design, synthesis, biological evaluation, and X-ray crystallography. J Med Chem 2016;59:114–31.
   PubMed Web of Science ®Google Scholar
• Tang WJ, Wang J, Tong X, et al. Design and synthesis of celastrol derivatives as anticancer agents. Eur J Med Chem 2015;95:166–73.
   PubMed Web of Science ®Google Scholar